Its heralded by celebrities and influencers alike, and its led to powerful physical transformations for a variety of people
This shows GLP-1 medications like Zepbound could greatly improve patient care
A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction
The Drug Boom That Needs a Fridge Most injectable GLP-1 drugs, such as Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, require cold-chain conditions during transport
doi: 10.2337/db10-1332 56 ElliottRMMorganLMTredgerJADeaconSWrightJMarksV
T., Yi, P., Li, Y., Hueng, C., & Xiao, W